Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs. trastuzumab plus taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE.

Affiliation auteurs!!!! Error affiliation !!!!
TitrePhase III, randomized study of first-line trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs. trastuzumab plus taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE.
Type de publicationJournal Article
Year of Publication2017
AuteursPerez EA, Barrios CH, Eiermann W, Toi M, Im Y-H, Conte PFranco, Martin M, Pienkowski T, Pivot XB, Burris HA, Hoersch S, Patre M, Ellis PAnthony
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume35
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2017.35.15_suppl.1003